Dyne Therapeutics, Inc.
DYN evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $3.79B
- Lead Asset:
- DYNE-101 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for DYN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DYN
Dyne Therapeutics is a clinical-stage biotech company developing FORCE platform-based oligonucleotide therapeutics for genetically driven neuromuscular diseases, with lead programs in Duchenne muscular dystrophy (z-rostudirsen) and myotonic dystrophy type 1 (z-basivarsen).
Key risk: Clinical development uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials · 1 catalyst for Dyne Therapeutics, Inc..
Similar companies
Dyne Therapeutics is a clinical-stage biotech company developing FORCE platform-based oligonucleotide therapeutics for genetically driven neuromuscular diseases, with lead programs in Duchenne muscular dystrophy (z-rostudirsen) and myotonic dystrophy type 1 (z-basivarsen).
- Cash and equivalents of $676.1M as of 2026-06-30, with an expected cash runway into the first quarter of 2028 [sec · filed 2026-04-23] [sec].
- Lead DMD program z-rostudirsen met its primary endpoint in the registrational expansion cohort of the DELIVER trial, showing a statistically significant increase in muscle dystrophin at six months [sec · filed 2026-04-23].
- DM1 program z-basivarsen completed the multiple ascending dose portion of the ACHIEVE trial in January 2025 [sec · filed 2026-04-23].
- Net income of -$178.6M and shareholders' equity of $702.2M as of 2026-06-30 [sec].
- Total debt of $200.0M as of 2026-06-30 [sec].
What works
- Strong cash position of $676.1M as of 2026-06-30 provides a runway into early 2028, supporting ongoing clinical and commercial preparations [sec].
- The DELIVER trial for z-rostudirsen met its primary endpoint with a statistically significant increase in dystrophin and showed functional improvement across multiple endpoints [sec · filed 2026-04-23].
- The company has built out commercial and manufacturing teams to prepare for a potential launch of z-rostudirsen [sec · filed 2026-04-23].
What to weigh
- The company reported a net loss of $178.6M for the six months ended 2026-06-30, reflecting high R&D spending [sec].
- Total debt of $200.0M as of 2026-06-30 adds financial obligations [sec].
- The successful development of any product candidate is highly uncertain due to numerous risks including clinical trial timing, regulatory paths, and funding needs [sec_mda · as of 2026-07-29].
From the filings
Quoted directly from source documents.
Cash runway extended into first quarter of 2028
“on our capital strategy to extend our expected cash runway into the first quarter of 2028.”
SEC filings · April 23, 2026
DELIVER trial met primary endpoint
“The registrational expansion cohort met its primary endpoint of demonstrating a statistically significant increase in muscle content-adjusted dystrophin at six months”
SEC filings · April 23, 2026
Z-basivarsen completed MAD portion
“In January 2025, we announced the completion of the multiple ascending dose portion of the trial”
SEC filings · April 23, 2026
Catalyst timeline
- 2027-01-21 · PDUFA — PDUFA target action date for z-rostudirsen (DMD) review by the FDA.
Risks & what to watch (3)›
Key risks
- Clinical development uncertainty — The successful development of any product candidate is highly uncertain due to numerous risks including clinical trial timing, regulatory paths, and funding needs [sec_mda · as of 2026-07-29].
- Net loss and debt burden — Net loss of $178.6M and total debt of $200.0M as of 2026-06-30 pressure financial sustainability [sec].
- Regulatory and commercial risks — Dependence on regulatory approval and successful launch for z-rostudirsen and z-basivarsen [sec · filed 2026-04-23].
What to watch
- PDUFA date for z-rostudirsen on 2027-01-21 [catalyst].
- Progress of the Phase 3 ACHIEVE trial for z-basivarsen in DM1 [sec · filed 2026-04-23].
- Cash burn rate and any additional financing activities as the company approaches 2028 [sec · filed 2026-04-23].
- Regulatory submissions and potential launch readiness for z-rostudirsen [sec · filed 2026-04-23].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 14, 2026 · How we verify sources →
Run Dyne Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Dyne Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.42
Lead: Phase 3
2 candidates
1 upcoming, next in ~99d
4 buys · 102 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 13.6%
- Days to cover
- 7.7
- Shares short
- 20,465,591
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DYN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Dyne Therapeutics, Inc.?
Dyne Therapeutics is a clinical-stage biotech company developing FORCE platform-based oligonucleotide therapeutics for genetically driven neuromuscular diseases, with lead programs in Duchenne muscular dystrophy (z-rostudirsen) and myotonic dystrophy type 1 (z-basivarsen).
What is Dyne Therapeutics, Inc.'s lead drug candidate?
Dyne Therapeutics, Inc.'s most advanced tracked candidate is DYNE-101 (Phase 3) for Myotonic Dystrophy Type 1 (DM1).
What is Dyne Therapeutics, Inc.'s next catalyst?
Dyne Therapeutics, Inc.'s next tracked catalyst is a PDUFA event — "PDUFA: 0001193125-26-308343" — expected January 21, 2027.
Who is the CEO of Dyne Therapeutics, Inc.?
Mr. John G. Cox M.B.A. is the chief executive officer of Dyne Therapeutics, Inc. (DYN).
Where is Dyne Therapeutics, Inc. headquartered?
Dyne Therapeutics, Inc. (DYN) is headquartered in Waltham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.